Survodutide
Product Overview
Survodutide (BI 456906) is an investigational synthetic peptide and dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors, developed by Boehringer Ingelheim. Scientific literature and clinical trials have examined its effects on metabolic parameters including body weight and liver fat in research settings. Note: Survodutide is an investigational compound and not an approved medicine.
Research Information
Survodutide (BI 456906) is an investigational synthetic peptide and dual agonist of glucagon-like peptide-1 (GLP-1) and glucagon receptors, developed by Boehringer Ingelheim. Scientific literature and clinical trials have examined its effects on metabolic parameters including body weight and liver fat in research settings. Note: Survodutide is an investigational compound and not an approved medicine.
Research Classification
Investigational — Not for human consumption. Not an approved medicine unless otherwise noted. Intended for laboratory, scientific, or clinical research contexts as permitted by applicable law.
